- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03815916
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease (REPAIR-PD)
A Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Parkinson's Disease
Study Overview
Detailed Description
This is a single-center open label pilot, sequential group, investigator blinded study of the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been diagnosed with Parkinson's Disease within three years of Screening. The Sponsor will select a starting treatment dose of CNM-Au8 for the initial treatment. Investigators and patients will be blinded to each cohort's study dose. Upon completion of the first treatment cohort, the Sponsor will select a single dose or two different doses for the subsequent second cohort from a pre-specified dosing selection plan based on the evaluation of the 31P-Magnetic Resonance Spectroscopy (31P-MRS) changes versus baseline in the first cohort. Up to a total of two treatment cohorts may be studied (n=15 patients/cohort, total n=30 patients). All patients will receive daily oral treatment over twelve consecutive weeks during each cohort's Treatment Period.
There will be three study periods per treatment cohort:
- A six-week screening period (Screening Period);
- A twelve-week treatment period (Treatment Period);
- A four-week follow-up period (End-of-Study Assessment).
The primary study outcome, CNS metabolic changes, will be assessed based upon each patient's Week 12 study visit versus the pre-treatment baseline. The primary endpoint is the brain metabolic effects of treatment with CNM-Au8 as assessed by an improvement of 31P-MRS assessment of Brain Tissue Cellular Redox Potential defined by the measured tissue ratio of NAD+:NADH concentrations following 12 weeks of once daily treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to understand and give written informed consent and follow study procedures.
- Male or female, aged 30 - 80 years or age (inclusive) at the time of PD diagnosis.
PD subjects will be recruited in accordance with the MDS Clinical Diagnostic Criteria for
PD:
- Parkinsonism present (bradykinesia + either rest tremor or rigidity)
- 2 of the following 4 supportive criteria:
i. Clear and dramatic beneficial response to dopaminergic medication
ii. Presence of levodopa-induced dyskinesias
iii. Rest tremor of a limb
iv. Olfactory loss or cardiac sympathetic denervation seen on prior MIBG SPECT
- Duration of PD since diagnosis is </= 3 years (inclusive)
- Modified Hoehn and Yahr stage </= 3
- Treatment with dopaminergic therapy for at least 12-weeks and with no change in current medications within the prior 6-weeks
Exclusion Criteria:
- Atypical parkinsonism, including that due to drugs, metabolic disorders, encephalitis, cerebrovascular disease, normal pressure hydrocephalus, or other neurodegenerative disease.
The presence of any of the following:
- Unequivocal cerebellar abnormalities
- Downward vertical gaze limitation or slowing of downward saccades
- Diagnosis of behavioral variant frontotemporal dementia or primary progressive aphasia
- Parkinsonian features restricted to the lower limbs for > 3 years
- Treatment with dopamine blockers or depleters in a time course consistent with drug-induced parkinsonism
- Absence of an observable response to high dose levodopa despite moderate disease severity
- Expert considers a diagnosis of alternative syndrome more likely than PD
- Rapid progression of gait impairment requiring wheelchair within 5 years of onset
- Complete absence of progression of motor symptoms over 3 years unless due to treatment
- Early bulbar dysfunction within the first 5 years since diagnosis
- Inspiratory respiratory dysfunction (stridor or frequent sighs)
- Severe autonomic failure in the first 5 years
- Recurrent falls (>1 per year) because of impaired balance in the first 3 years
- Disproportionate dystonic anterocollis or hand contractures of hands or feet within 10 years
- Absence of any of the common non-motor features of PD despite 5 years of disease
- Otherwise unexplained pyramidal tract signs (weakness, hyperreflexia, or extensor toe signs)
- Bilateral symmetric parkinsonism
- Mini-Mental State Exammination (MMSE) score of less than 19.
- Patient with a history of any clinically significant or unstable medical condition based on the Investigator's judgment.
- History of human immunodeficiency virus (HIV), hepatitis C (HepC) virus antibody, or hepatitis B (HepB) virus antibody.
- Based on the investigator's judgment, patients who may have difficulty complying with the protocol and/or study procedures.
- Patient with clinically significant abnormalities in hematology, blood chemistry, ECG, or physical examination not resolved by the Baseline visit which according to Investigator may interfere with study participation.
- Patients with clinically significant hepatic or renal dysfunction or clinical laboratory findings that would limit the interpretability of change in liver or kidney function, or those with low platelet counts (<150 x 109 per liter) or eosinophilia (absolute eosinophil count of ≥500 eosinophils per microliter) at Screening.
- Patient participating in any other investigational drug trial or using investigational drug (within 12 weeks prior to screening and thereafter)
- Positive screen for drugs of abuse or known history of alcohol abuse.
- Women of child-bearing potential, or men, who are unwilling or unable to use accepted methods of birth control for up to 6 months following study participation.
- Women with a positive pregnancy test, are lactating, or are planning to become pregnant during the study or within 6 months of the end of this trial.
- Patients with implanted metal objects in their body that may be affected by an MRI procedure.
- Patients who are claustrophobic or otherwise unlikely to be able to complete the MRI scanning procedures.
- History of allergy to gold in any form.
- Patient is considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the Investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 7.5mg CNM-Au8
7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
|
CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold.
The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL.
There are no other excipients.
The drug product is formulated to be taken orally and will be provided in single dose HDPE containers.
The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
Other Names:
|
Experimental: 15mg CNM-Au8
15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
|
CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold.
The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL.
There are no other excipients.
The drug product is formulated to be taken orally and will be provided in single dose HDPE containers.
The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
Other Names:
|
Experimental: 30mg CNM-Au8
30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
|
CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold.
The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL.
There are no other excipients.
The drug product is formulated to be taken orally and will be provided in single dose HDPE containers.
The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
Other Names:
|
Experimental: 60mg CNM-Au8
60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
|
CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold.
The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL.
There are no other excipients.
The drug product is formulated to be taken orally and will be provided in single dose HDPE containers.
The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in 31P-MRS Redox Ratio (NAD+/NADH)
Time Frame: At 12 Weeks
|
Mean change in average NAD+/NADH measured brain Redox Ratio by treatment group
|
At 12 Weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in 31P-MRS Membrane Component Tissue Concentration of Phosphoethanolamine (PE)
Time Frame: At 12 Weeks
|
Mean change in average CNS concentration of PE [mmol/kg] by treatment group
|
At 12 Weeks
|
Mean Change in 31P-MRS Membrane Component CNS Tissue Concentration of Phosphocholine (PC)
Time Frame: At 12 Weeks
|
Mean change in average CNS concentration of PC [mmol/kg] by treatment group
|
At 12 Weeks
|
Mean Change in 31P-MRS Membrane Component CNS Tissue Concentration of Glycerophosphocholine (GPC)
Time Frame: At 12 Weeks
|
Mean change in average CNS concentration of GPC [mmol/kg] by treatment group
|
At 12 Weeks
|
Mean Change in 31P-MRS Bioenergetic Metabolite CNS Tissue Concentration of NAD+
Time Frame: At 12 Week
|
Mean change in average CNS concentration of NAD+ [mmol/kg] by treatment group
|
At 12 Week
|
Mean Change in 31P-MRS Bioenergetic Metabolite CNS Tissue Concentration of NADH
Time Frame: At 12 Week
|
Mean change in average CNS concentration of NADH [mmol/kg] by treatment group
|
At 12 Week
|
Mean Change in 31P-MRS Bioenergetic Metabolite CNS Tissue Concentration of Pooled NAD+/NADH
Time Frame: At 12 Weeks
|
Mean change in average CNS concentration of pooled NAD+/NADH [mmol/kg] by treatment group
|
At 12 Weeks
|
Mean Change in 31P-MRS Bioenergetic Metabolite CNS Tissue Concentration of ATP
Time Frame: At 12 Week
|
Mean change in average CNS concentration of ATP [mmol/kg] (as internal reference) by treatment group
|
At 12 Week
|
Mean Change in 31P-MRS Bioenergetic Metabolite CNS Tissue Concentration of Phosphocreatine (PCr)
Time Frame: At 12 Week
|
Mean change in average CNS concentration of PCr [mmol/kg] by treatment group
|
At 12 Week
|
Mean Change in 31P-MRS Bioenergetic Metabolite CNS Tissue Concentration of Intracellular Inorganic Phosphate (Pi(in))
Time Frame: At 12 Week
|
Mean change in average CNS concentration of Pi(in) [mmol/kg] by treatment group
|
At 12 Week
|
Mean Change in 31P-MRS Bioenergetic Metabolite CNS Tissue Concentration of Extracellular Inorganic Phosphate (Pi(ex))
Time Frame: At 12 Week
|
Mean change in average CNS concentration of Pi(ex) [mmol/kg] by treatment group
|
At 12 Week
|
Mean Change in 31P-MRS Bioenergetic Metabolite CNS Tissue Concentration of Uridine Diphosphate Glucose (UDPG)
Time Frame: At 12 Week
|
Mean change in average CNS concentration of UDPG [mmol/kg] by treatment group
|
At 12 Week
|
Mean Change in 31P-MRS Membrane Component CNS Tissue Concentration of Glycerolphophoethanolamine (GPE)
Time Frame: At 12 Weeks
|
Mean change in average CNS concentration of GPE [mmol/kg] by treatment group
|
At 12 Weeks
|
Measures of Gait
Time Frame: at 12 weeks
|
Measured by APDM instrumented Timed up and go test.
|
at 12 weeks
|
Measures of Balance
Time Frame: at 12 weeks
|
Measured by APDM Instrumented Postural Sway Test
|
at 12 weeks
|
Measure of Mobility
Time Frame: at 12 weeks
|
Measured by APDM instrumented Walk Test
|
at 12 weeks
|
Measurements of Global Impression of Disease Improvement
Time Frame: at 12 weeks
|
Using Clinician Global Impression Scale.
Scale is rated from 1-7, with 1 representing Very much improved and 7 representing very much worse.
|
at 12 weeks
|
Measurements of Global Impression of Disease Severity
Time Frame: at 12 weeks
|
Using Patient Global Impression Scale.
Scale is rated from 1-7, with 1 representing very mush improved, and 7 representing very much worse.
|
at 12 weeks
|
Measurements of disease progression
Time Frame: at 12 weeks
|
Using Unified Parkinson's Disease Rating Scale.
The scale is based off of participants symptoms, with a lower value representing a being closer to no impairments.
|
at 12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Richard Dewey, MD, UT Southwestern
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CNMAu8.202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
BlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterActive, not recruitingAdvanced Parkinson's DiseaseUnited States, Canada
Clinical Trials on Gold Nanocrystals
-
Clene NanomedicineUniversity of Texas Southwestern Medical CenterWithdrawnAmyotrophic Lateral SclerosisUnited States
-
Clene NanomedicineUniversity of Texas Southwestern Medical CenterRecruitingMultiple SclerosisUnited States
-
Clene NanomedicineCompletedHealthy Volunteers - Male and FemaleNetherlands
-
NestléCompletedStool CompositionPhilippines
-
4Life Research, LLCSt. Louis University; Professional Athletic OrthopedicsCompletedRheumatoid Arthritis | Knee Osteoarthritis | Knee Arthritis | Knee Discomfort | Knee Pain Chronic | Knee Pain SwellingUnited States
-
Gitte Fredberg PerssonCompleted
-
Sten Rasmussen, MD, PhDAalborg UniversityCompleted
-
Tongji HospitalShanghai Zhongshan Hospital; Peking University Third Hospital; Huashan Hospital; First Affiliated Hospital Xi'an Jiaotong University and other collaboratorsCompleted
-
Northern Orthopaedic Division, DenmarkAarhus University Hospital; University of AarhusWithdrawn
-
Northern Orthopaedic Division, DenmarkAalborg UniversityNot yet recruitingAllergic Reaction